Korea Quality Re-Rating Watch Oct 26: BioLogics, TFE, Bear Breadth

Mon, 26 Oct 2026 16:30:00 +0900

Macro Dashboard

Indicator	Level	5-Day Change	Signal
KOSPI	5,469.5	−1.5%	Flat
KOSDAQ	727.2	−7.0%	Weak
USD/KRW	1,324	−0.4%	Stable
VIX	19.67	+13.6%	Elevated
Brent	$109.92	+1.0%	Firm
US 10Y	4.99%	−15bp	Easing

KR Regime: Bear. Only 19.1% of tracked Korean equities trade above their 50-day moving average (out of 2,688 names). KOSDAQ’s 7% five-day slide is the primary driver.
US Regime: Bull. Nasdaq and S&P 500 remain above their 200-day MAs; VIX at 19.67 stays below the 20-point caution threshold; the 10Y/2Y curve holds at +31bp.
KR AA− corporate credit spread vs KTB 3Y: 69bp, broadly stable over the week.

Market Wrap

Source: KR Market Snapshot DB (2026-10-26). No same-day full close briefing was generated; this section draws from the close-of-day market database.

October 26 was a broad selloff with little place to hide. Of 2,593 tracked Korean equities, 1,928 declined and only 447 advanced — an ADR proxy of 23.2% and an average stock return of −1.75%. That is bear-market breadth, not selective sector rotation.

The headline KOSPI/KOSDAQ divergence carries the week’s clearest signal. KOSPI is down 1.5% over five sessions; KOSDAQ is down 7.0%. The gap points to sustained selling in small- and mid-cap growth: semiconductor equipment, KOSDAQ tech hardware, and select consumer names absorbed the heaviest damage. Large-cap defensives and IT services held comparatively better.

Passive outflows amplified the pressure. ETF net redemptions totaled −₩1.18 trillion, with market program net selling at −₩527bn. The futures basis sat at −1.51 — deeply negative — flagging limited demand for leveraged index exposure.

Foreign flow was fragmented. Foreigners net-bought into weakness on 두산 (000150.KS, −6.5%), S-Oil (010950.KS, −3.6%), NAVER (035420.KS, +0.4%), and 삼성E&A (028050.KS). They were net sellers across financials — BNK금융지주 (138930.KS, −13.8%), KB금융 (105560.KS, −3.8%), 우리금융지주 (316140.KS, −2.8%) — and sold out of 삼성에스디에스 (018260.KS) and LG씨엔에스 (064400.KS) in IT services.

Institutions moved in the opposite direction on those IT services names, net-buying 삼성에스디에스, LG씨엔에스, 삼성생명 (032830.KS), and 삼성물산 (028260.KS) while foreigners sold. Domestic institutions absorbing foreign supply in large-cap IT services was one of the few conviction flows on the session. Elsewhere, institutions sold cyclicals and energy: 한화솔루션 (009830.KS, −6.9%), 피에스케이 (319660.KS, −7.2%), 삼양식품 (003230.KS, −8.9%), and HPSP (403870.KQ, −5.9%).

The overall character: risk-off, broad-based, and KOSDAQ-led. Semiconductor equipment, regional banks, energy, and consumer discretionary absorbed the brunt. The session was not selective — it was a tide going out.

Today’s Quality Re-Rating Candidates

Source: KR Meta Screener (2026-10-26, all screener sources fresh). The Screener Intersection Summary included only PEAD for today’s raw-overlap table and returned no 2+ screener matches; the Meta Screener synthesizes quality, smart money, cycle rerating, earnings, consensus revision, RS80, and official DART signals across a 111-ticker candidate universe.

Despite the broad selloff, the meta screener surfaces names where institutional and foreign capital is entering against retail supply — the exact setup this framework is designed to flag.

Top Screened Candidates

Rank	Ticker	Name	Meta Score	Evidence Families	Key Screener Signals	Key Metrics
1	207940.KS	Samsung BioLogics	56.3	5	Cycle Rerating, PEAD, SM Earnings, SM Quality	OPM 45.4%, Δmargin +7.6pp, F+QI net buy +₩125bn (5D)
2	425420.KQ	TFE	49.3	3	Quality Compounder, Cycle Rerating, SM Earnings, SM Quality	ROE 16.6%, OP YoY +334%, Δmargin +11.1pp
3	089890.KQ	Koses	48.1	4	Cycle Rerating, Consensus Up, SM Quality	Δmargin +29.2pp, F+QI net buy +₩17bn (5D)
4	086450.KS	Dong Kook Pharm	44.5	3	Quality Compounder, Cycle Rerating	ROE 9.9%, OP YoY +20.1%, Δmargin +0.5pp
5	003350.KS	Korea Cosmetics Mfg	43.1	4	Quality Compounder, Cycle Rerating, SM Earnings, SM Quality	ROE 30.6%, OP YoY +24.2%, Δmargin +2.0pp
6	021240.KS	Coway	40.3	4	Quality Compounder, RS80 Not-Late	ROE 17.1%, OP YoY +10.5%, pivot gap +8.2%
7	068270.KS	Celltrion	38.7	4	Cycle Rerating, RS80 Not-Late	Δmargin +14.2pp, 5× DART catalyst filings
8	089860.KS	Lotte Rental	35.8	4	Cycle Rerating, RS80 Not-Late	Δmargin +0.5pp, earnings preview DART filed
9	098120.KQ	Microcontact Sol	34.6	5	SM Earnings, SM Quality, Kiwoom Surface	F+QI net buy +₩3.5bn (5D)
10	420770.KQ	Gigavis	34.4	5	SM Earnings, SM Quality, PEAD	F+QI net sell −₩3.3bn absorbed by retail +₩3.7bn

SM = Smart Money. All data as of 2026-10-26. Note: Gigavis (420770.KQ) shows institutional/foreign net selling absorbed by retail — the inversion of the preferred setup; treat with caution.

Top 3 in Focus

Samsung BioLogics (207940.KS) — Meta Rank #1 Korea’s largest contract drug manufacturer. The meta screener ranks it first not on the Quality Compounder signal alone, but because all five independent evidence families are firing together: the earnings-cycle axis (OPM expanded 7.6pp to 45.4%), PEAD (price still adjusting to the last earnings print), smart money quality (foreigners and quality institutions net-bought ₩125bn over five days while retail distributed ₩84bn), and DART filings (three insider ownership reports filed Oct 26). The key question to verify next: whether the operating margin expansion reflects structural capacity-utilization improvement in biologics CDMO contracts, or a one-period mix shift.

TFE (425420.KQ) — Meta Rank #2 A semiconductor and display equipment components maker that clears every primary screen simultaneously — the only name in the top-10 with Quality Compounder, Cycle Rerating, Smart Money Quality, and Smart Money Earnings all active. Operating profit grew 334% YoY with margin expanding 11.1pp; ROE stands at 16.6%. Foreign and quality institutional investors net-bought ₩24bn against retail selling ₩38bn over five days. Its raw meta score (77.6) is the highest in the table; the family-adjusted score (49.3) is lower because the scoring caps same-family evidence to avoid double-counting correlated signals. Next check: determine whether the earnings base was abnormally depressed a year ago, or whether the margin inflection reflects a durable product-mix or utilization shift.

Korea Cosmetics Manufacturing (003350.KS) — Meta Rank #6, three primary signals active An OEM/ODM cosmetics formulator running the highest ROE in the top-10 at 30.6%. Operating profit grew 24.2% YoY with 2pp of margin expansion, and smart money is net-buying over five days (F+QI +₩31bn vs retail −₩27bn). Like TFE, it clears all three primary screens: Quality Compounder, Cycle Rerating, and Smart Money Quality — which is why it deserves attention above its raw rank of sixth. One caution flags in the DART overlay: a convertible-right exercise was filed on Oct 7, classified as a risk disclosure. The next check is whether the potential dilution is material relative to the earnings trajectory that drove the screener inclusion.

Korea Cosmetics Manufacturing on Korea Invest Insights

Korea Quality Re-Rating Watch Oct 26: BioLogics, TFE, Bear Breadth

Macro Dashboard

Market Wrap

Today’s Quality Re-Rating Candidates

Top Screened Candidates

Top 3 in Focus